Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Haptoglobin and Preeclampsia

This study has been completed.
Information provided by:
Bnai Zion Medical Center Identifier:
First received: December 4, 2009
Last updated: NA
Last verified: December 2009
History: No changes posted

The purpose of this study is to show that a certain protein called haptoglobin protects against preeclampsia which is a common pregnancy complication.


Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Bnai Zion Medical Center:

healthy control
240 female subjects without preeclampsia
120 female subjects with preeclampsia


Genders Eligible for Study:   Female
Sampling Method:   Non-Probability Sample
Study Population

women coming to give birth at our medical center


Inclusion Criteria:

  • all women

Exclusion Criteria:

  • women with hypertension
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01027130

Bnai-Zion Medical Center
Haifa, Israel, 33393
Sponsors and Collaborators
Bnai Zion Medical Center
  More Information

No publications provided Identifier: NCT01027130     History of Changes
Other Study ID Numbers: HAPPET
Study First Received: December 4, 2009
Last Updated: December 4, 2009
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Hypertension, Pregnancy-Induced
Pregnancy Complications processed this record on November 25, 2014